Drug Profile
PPL 003
Alternative Names: PPL-003Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Portage Biotech
- Developer EyGen; Portage Biotech
- Class Anti-inflammatories; Eye disorder therapies; Peptides; Recombinant fusion proteins
- Mechanism of Action NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dry eyes; Neurological disorders; Uveitis
Most Recent Events
- 27 Sep 2023 Discontinued - Preclinical for Dry eyes in USA (Topical)
- 27 Sep 2023 Discontinued - Preclinical for Neurological disorders in USA (unspecified route)
- 27 Sep 2023 Discontinued - Preclinical for Uveitis in USA (Topical)